PVLAPalvella Therapeutics, Inc.
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and big price swings.
Insiders were net sellers (-$6.2M, 90 days to Oct 8, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -99% · now 12% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can PVLA take a bad year?
The deepest fall in PVLA's price history on file is −99%; it is 12% below its high today.
Worst drawdown on file · −12% today
- Annualised volatility
- 77%
Annualised volatility · three times the market's own swing
Details›
- Annualised volatilitytwo years of daily moves
- 77%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 12%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry